NCT03797326 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 102
- group Id
- BG003
- value
- 107
- group Id
- BG004
- value
- 32
- group Id
- BG005
- value
- 102
- group Id
- BG006
- value
- 103
- group Id
- BG007
- value
- 103
- group Id
- BG008
- value
- 611
- units
- Participants
- groups
- description
- Participants received Pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenvatinib (lenva) 20 mg via oral capsule once a day (QD) up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG000
- title
- Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG001
- title
- Cohort B: Ovarian Cancer (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG002
- title
- Cohort C: Gastric Cancer (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG003
- title
- Cohort D1: Colorectal Cancer (Lenva + Pembro)
- description
- Participants received Lenva 24 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG004
- title
- Cohort D2: Colorectal Cancer (Lenva)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG005
- title
- Cohort E: Glioblastoma Multiforma (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG006
- title
- Cohort F: Biliary Tract Cancer (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG007
- title
- Cohort G: Pancreatic Cancer (Lenva + Pembro)
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 68
- group Id
- BG003
- value
- 71
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 83
- group Id
- BG006
- value
- 52
- group Id
- BG007
- value
- 56
- group Id
- BG008
- value
- 398
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 34
- group Id
- BG003
- value
- 36
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 51
- group Id
- BG007
- value
- 47
- group Id
- BG008
- value
- 213
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 32
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 38
- group Id
- BG006
- value
- 53
- group Id
- BG007
- value
- 42
- group Id
- BG008
- value
- 271
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 72
- group Id
- BG003
- value
- 75
- group Id
- BG004
- value
- 18
- group Id
- BG005
- value
- 64
- group Id
- BG006
- value
- 50
- group Id
- BG007
- value
- 61
- group Id
- BG008
- value
- 340
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 19
- group Id
- BG004
- value
- 9
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 16
- group Id
- BG008
- value
- 91
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 64
- group Id
- BG003
- value
- 77
- group Id
- BG004
- value
- 23
- group Id
- BG005
- value
- 73
- group Id
- BG006
- value
- 76
- group Id
- BG007
- value
- 86
- group Id
- BG008
- value
- 441
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 18
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 79
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 17
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 17
- group Id
- BG006
- value
- 18
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 82
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 70
- group Id
- BG003
- value
- 71
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 72
- group Id
- BG006
- value
- 71
- group Id
- BG007
- value
- 90
- group Id
- BG008
- value
- 444
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 13
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 13
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 60
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 102
- group Id
- BG003
- value
- 107
- group Id
- BG004
- value
- 32
- group Id
- BG005
- value
- 102
- group Id
- BG006
- value
- 103
- group Id
- BG007
- value
- 103
- group Id
- BG008
- value
- 611
- units
- Participants
- groups
- description
- Participants received Pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenvatinib (lenva) 20 mg via oral capsule once a day (QD) up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG000
- title
- Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG001
- title
- Cohort B: Ovarian Cancer (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG002
- title
- Cohort C: Gastric Cancer (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG003
- title
- Cohort D1: Colorectal Cancer (Lenva + Pembro)
- description
- Participants received Lenva 24 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG004
- title
- Cohort D2: Colorectal Cancer (Lenva)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG005
- title
- Cohort E: Glioblastoma Multiforma (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG006
- title
- Cohort F: Biliary Tract Cancer (Lenva + Pembro)
- description
- Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.
- id
- BG007
- title
- Cohort G: Pancreatic Cancer (Lenva + Pembro)
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 68
- group Id
- BG003
- value
- 71
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 83
- group Id
- BG006
- value
- 52
- group Id
- BG007
- value
- 56
- group Id
- BG008
- value
- 398
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 34
- group Id
- BG003
- value
- 36
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 51
- group Id
- BG007
- value
- 47
- group Id
- BG008
- value
- 213
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 32
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 38
- group Id
- BG006
- value
- 53
- group Id
- BG007
- value
- 42
- group Id
- BG008
- value
- 271
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 72
- group Id
- BG003
- value
- 75
- group Id
- BG004
- value
- 18
- group Id
- BG005
- value
- 64
- group Id
- BG006
- value
- 50
- group Id
- BG007
- value
- 61
- group Id
- BG008
- value
- 340
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 19
- group Id
- BG004
- value
- 9
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 16
- group Id
- BG008
- value
- 91
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 64
- group Id
- BG003
- value
- 77
- group Id
- BG004
- value
- 23
- group Id
- BG005
- value
- 73
- group Id
- BG006
- value
- 76
- group Id
- BG007
- value
- 86
- group Id
- BG008
- value
- 441
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 18
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 79
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 17
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 17
- group Id
- BG006
- value
- 18
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 82
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 70
- group Id
- BG003
- value
- 71
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 72
- group Id
- BG006
- value
- 71
- group Id
- BG007
- value
- 90
- group Id
- BG008
- value
- 444
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 13
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 13
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 60
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle